|Nome||Titolo||Retribuzione||Esercitate||Anno di nascita|
|Dr. Nancy A. Simonian M.D.||Pres, CEO & Director||1,03M||N/D||1961|
|Dr. Richard A. Young Ph.D.||Scientific Founder, Member of Scientific Advisory Board & Director||165k||N/D||1954|
|Dr. Eric R. Olson||Chief Scientific Officer||696,42k||N/D||1958|
|Dr. David A. Roth||Chief Medical Officer||713,03k||N/D||1963|
|Dr. James E. Bradner M.D.||Founder||N/D||N/D||1972|
|Dr. Nathanael S. Gray Ph.D.||Scientific Founder & Member of Scientific Advisory Board||N/D||N/D||N/D|
|Mr. Jason Haas||Chief Financial Officer||N/D||N/D||N/D|
|Mr. Gerald E. Quirk||Chief Operations Officer & Sec.||N/D||N/D||1968|
|Ms. Naomi Aoki||VP of Corp. Communications & Investor Relations||N/D||N/D||N/D|
|Dr. Christian C. Fritz Ph.D.||Head of Biology||N/D||N/D||N/D|
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
L'ISS Governance QualityScore di Syros Pharmaceuticals, Inc. al 26 settembre 2021 è 7. I criteri di valutazione fondamentali sono revisione: 6; Consiglio di Amministrazione: 6; diritti degli azionisti: 8; retribuzione: 8.